GCTK vs. AVGR, NAYA, QNRX, AFIB, TTOO, NVIVQ, SONX, DYNT, BIOL, and SDCCQ
Should you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include Avinger (AVGR), NAYA Biosciences (NAYA), Quoin Pharmaceuticals (QNRX), Acutus Medical (AFIB), T2 Biosystems (TTOO), Invivo Therapeutics (NVIVQ), Sonendo (SONX), Dynatronics (DYNT), BIOLASE (BIOL), and SmileDirectClub (SDCCQ). These companies are all part of the "medical equipment" industry.
GlucoTrack vs.
Avinger (NASDAQ:AVGR) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.
Avinger received 393 more outperform votes than GlucoTrack when rated by MarketBeat users.
In the previous week, Avinger had 3 more articles in the media than GlucoTrack. MarketBeat recorded 3 mentions for Avinger and 0 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.00 beat Avinger's score of -0.36 indicating that GlucoTrack is being referred to more favorably in the news media.
18.3% of Avinger shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 42.8% of Avinger shares are owned by insiders. Comparatively, 46.5% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Avinger has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, GlucoTrack has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.
GlucoTrack has a net margin of 0.00% compared to Avinger's net margin of -261.06%. GlucoTrack's return on equity of -826.43% beat Avinger's return on equity.
GlucoTrack has lower revenue, but higher earnings than Avinger. Avinger is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.
Avinger currently has a consensus price target of $5.00, indicating a potential upside of 954.85%. Given Avinger's stronger consensus rating and higher probable upside, research analysts plainly believe Avinger is more favorable than GlucoTrack.
Summary
Avinger beats GlucoTrack on 10 of the 16 factors compared between the two stocks.
Get GlucoTrack News Delivered to You Automatically
Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GlucoTrack Competitors List
Related Companies and Tools
This page (NASDAQ:GCTK) was last updated on 2/22/2025 by MarketBeat.com Staff
Free GCTK Stock Alerts